肝外胆管癌患者癌组织与血清中PLK1、Aurora A水平的变化及其临床意义
| 作者: |
1崔学振,
2尚培中
1 承德医学院，河北 承德 067000 2 中国人民解放军第二五一医院 普通外科，河北 张家口 075000 |
| 通讯: |
尚培中
Email: spz251@163.com |
| DOI: | 10.3978/.10.3978/j.issn.1005-6947.2016.08.011 |
摘要
目的：探讨有丝分裂调控酶polo样激酶1（PLK1）和Aurora A在肝外胆管癌患者癌组织及血清中的水平以及两者的临床意义。方法：用免疫组化法测定54例肝外胆管癌组织及20例癌旁胆管组织中PLK1和Aurora A的表达，用ELISA法检测25例肝外胆管癌患者与15例健康人血清中PLK1和Aurora A的浓度。分析两者表达与患者临床病理因素的关系，以及患者手术前后两者水平的变化。结果： 肝外胆管癌患者中，癌组织中PLK1和Aurora A的阳性表达率均明显高于癌旁胆管组织（66.7% vs. 25.0%；63.0% vs. 15.0%，均P<0.05），且PLK1和Aurora A的表达与肿瘤的分化程度、TNM分期和淋巴结转移密切有关（均P<0.05)；术前血清中PLK1和Aurora A的浓度均明显高于健康人群（434.85 pg/mL vs. 256.00 pg/mL；644.64 pg/mL vs. 375.73 pg/mL，均P<0.05），术后两者水平均明显降低（均P<0.05）；PLK1与Aurora A在肝外胆管癌患者癌组织中的表达量与血清中浓度具有一致性（r=0.55；r=0.64，均P<0.05）；无论癌组织或血清中，PLK1与Aurora A水平均呈正相关（癌组织：r=0.47，P<0.01；血清：r=0.71，P<0.01）。结论：PLK1与Aurora A水平在肝外胆管癌患者癌组织与血清均升高，且两者水平的升高与肝外胆管癌的恶性进展密切相关；两者联合检测对肝外胆管癌早期诊断、治疗效果及预后的判断有一定价值。
关键词：
胆管肿瘤
胆管，肝外
有丝分裂调节因子
Changes in PLK1 and Aurora A levels in tumor tissue and serum of patients with extrahepatic cholangiocarcinoma and their clinical significance
CorrespondingAuthor:SHANG Peizhong Email: spz251@163.com
Abstract
Objective: To investigate the levels of mitosis regulatory enzyme polo-like kinase 1 (PLK1) and Aurora A in tumor tissues and serum in patients with extrahepatic cholangiocarcinoma, and their clinical significance. Methods: The expressions of PLK1 and Aurora A in 54 tumor specimens of extrahepatic cholangiocarcinoma and 20 specimens of tumor adjacent bile duct tissue were determined by immunohistochemical staining, and the serum concentrations of PLK1 and Aurora A in 25 patients with extrahepatic cholangiocarcinoma and 15 healthy subjects were measured by ELISA assay. The relations of their expressions with clincopathologic factors of the patients and the changes in their serum levels in the patients before and after operation were analyzed. Results: In patients with extrahepatic cholangiocarcinoma, the positive expression rates of both PLK1 and Aurora A were significantly higher than those in tumor adjacent bile duct tissue (66.7% vs. 25.0%; 63.0% vs. 15.0%, both P<0.05), and their expressions were all significantly associated with degree of tumor differentiation, TNM stage and lymph node metastasis (all P<0.05). The preoperative serum concentrations of both PLK1 and Aurora A were significantly higher than those in healthy control population (434.85 pg/mL vs. 256.00 pg/mL;
644.64 pg/mL vs. 375.73 pg/mL, both P<0.05), which were significantly declined after operation (all P<0.05). The expression levels of PLK1 and Aurora A in tumor tissue and their serum concentrations had significant consistency (r=0.55; r=0.64, both P<0.05), and either in tumor tissue or serum, there was a significantly positive correlation between the levels of PLK1 and Aurora (tumor tissue: r=0.47, P<0.01; serum: r=0.71, P<0.01). Conclusion: The levels of both PLK1 and Aurora A are increased in either tumor tissue or peripheral blood in patients with extrahepatic cholangiocarcinoma, their elevations are closely related to the malignant progression of extrahepatic cholangiocarcinom and their combined detection may have certain value for early diagnosis and estimating therapeutic effect and prognosis of extrahepatic cholangiocarcinoma.
Keywords：
644.64 pg/mL vs. 375.73 pg/mL, both P<0.05), which were significantly declined after operation (all P<0.05). The expression levels of PLK1 and Aurora A in tumor tissue and their serum concentrations had significant consistency (r=0.55; r=0.64, both P<0.05), and either in tumor tissue or serum, there was a significantly positive correlation between the levels of PLK1 and Aurora (tumor tissue: r=0.47, P<0.01; serum: r=0.71, P<0.01). Conclusion: The levels of both PLK1 and Aurora A are increased in either tumor tissue or peripheral blood in patients with extrahepatic cholangiocarcinoma, their elevations are closely related to the malignant progression of extrahepatic cholangiocarcinom and their combined detection may have certain value for early diagnosis and estimating therapeutic effect and prognosis of extrahepatic cholangiocarcinoma.